BR112016029201A2 - vírus do oeste do nilo/dengue quiméricos e métodos de uso - Google Patents

vírus do oeste do nilo/dengue quiméricos e métodos de uso

Info

Publication number
BR112016029201A2
BR112016029201A2 BR112016029201A BR112016029201A BR112016029201A2 BR 112016029201 A2 BR112016029201 A2 BR 112016029201A2 BR 112016029201 A BR112016029201 A BR 112016029201A BR 112016029201 A BR112016029201 A BR 112016029201A BR 112016029201 A2 BR112016029201 A2 BR 112016029201A2
Authority
BR
Brazil
Prior art keywords
denv
serotype
chimera
methods
immune response
Prior art date
Application number
BR112016029201A
Other languages
English (en)
Other versions
BR112016029201B8 (pt
BR112016029201B1 (pt
Inventor
Y H Kinney Claire
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112016029201A2 publication Critical patent/BR112016029201A2/pt
Publication of BR112016029201B1 publication Critical patent/BR112016029201B1/pt
Publication of BR112016029201B8 publication Critical patent/BR112016029201B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

estão descritos aqui flavivírus quiméricos que incluem regiões não codificadoras, proteínas não estruturais e pelo menos uma porção de uma proteína c do vírus nilo (wnv) e uma proteína prm e uma proteína e do vírus da dengue (denv). o denv pode ser do sorotipo den1, sorotipo den2, sorotipo den3 ou sorotipo den4. também estão descritas aqui composições e métodos para desencadear uma resposta imune em um indivíduo tal como uma resposta imune a um ou mais sorotipos de denv. em modalidades particulares, as composições incluem um ou mais vírus inativados que incluem um ácido nucleico quimérico de wn/denv (tal como uma vacina inativada tetravalente que inclui uma quimera de wn/den1, uma quimera de wn/den2, uma quimera de wn/den3 e uma quimera de wn/den4). as composições podem ser administradas a um indivíduo para desencadear uma resposta imune.
BR112016029201A 2014-06-20 2015-06-19 Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus BR112016029201B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015265P 2014-06-20 2014-06-20
US62/015,265 2014-06-20
PCT/US2015/036728 WO2015196094A1 (en) 2014-06-20 2015-06-19 Chimeric west nile/dengue viruses and methods of use

Publications (3)

Publication Number Publication Date
BR112016029201A2 true BR112016029201A2 (pt) 2017-10-17
BR112016029201B1 BR112016029201B1 (pt) 2023-11-14
BR112016029201B8 BR112016029201B8 (pt) 2023-12-05

Family

ID=53524961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029201A BR112016029201B8 (pt) 2014-06-20 2015-06-19 Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus

Country Status (6)

Country Link
US (1) US10428313B2 (pt)
EP (1) EP3158061B1 (pt)
CN (1) CN106574271B (pt)
AU (1) AU2015276929B2 (pt)
BR (1) BR112016029201B8 (pt)
WO (1) WO2015196094A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481849A1 (en) 2016-07-08 2019-05-15 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
WO2018009603A1 (en) 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
US11634459B2 (en) 2017-08-18 2023-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric reporter West Nile/dengue viruses and their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939254A (en) 1997-04-28 1999-08-17 University Of Massachusetts Methods and reagents for rapid diagnosis of dengue virus infection
US6793488B1 (en) 1999-04-16 2004-09-21 U.S. Army Medical Research & Materiel Command Flavivirus detection and quantification assay
AU3844101A (en) * 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
AU2003205169A1 (en) 2002-01-15 2003-07-30 Acambis, Inc. Viral vaccine production method
EP1942932B1 (en) 2005-08-08 2013-05-08 Oregon Health and Science University Inactivating pathogens with hydrogen peroxide for vaccine production
MX2010010034A (es) 2008-03-14 2010-12-06 Sanofi Pasteur Biologics Co Vacunas de flavivirus defectuosas en replicacion y vectores de vacunas.
WO2009134717A1 (en) 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses

Also Published As

Publication number Publication date
US10428313B2 (en) 2019-10-01
BR112016029201B8 (pt) 2023-12-05
AU2015276929A1 (en) 2016-12-22
US20170114330A1 (en) 2017-04-27
EP3158061A1 (en) 2017-04-26
EP3158061B1 (en) 2019-08-07
CN106574271B (zh) 2020-06-16
CN106574271A (zh) 2017-04-19
BR112016029201B1 (pt) 2023-11-14
AU2015276929B2 (en) 2021-04-08
WO2015196094A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
UY35131A (es) Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4
CO2018006706A2 (es) Virus mutados, método de preparación y uso de los mismos
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
BR112017001310A2 (pt) coronavírus
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
BR112018071087A2 (pt) composições e métodos de vacinação contra o vírus da dengue em crianças e adultos jovens
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
MX2020004367A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
HRP20100314T1 (hr) Cjepivo protiv nipah virusa
JP2015524421A5 (pt)
PH12016502431A1 (en) Composition and methods for administration of vaccines against dengue virus
GEP20237575B (en) Stable vaccine compositions comprising inter alia live attenuated recombinant dengue virus and process for preparation thereof
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
AR100608A1 (es) Complejos de citomegalovirus y usos de los mismos
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
AR101814A1 (es) Partícula de tipo virus flavivirus
CR20140189S (es) Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
WO2012065105A3 (en) Chimeric flavivirus vaccines
GEP20237539B (en) Formulations of dengue virus vaccine compositions
PH12015502666A1 (en) Dengue virus vaccine compositions and methods of use thereof
PH12020550569A1 (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2758 DE14/11/2023, QUANTO AO ITEM (54) TITULO.